HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - A prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 55, Issue 5, 2015, Pages 493-497

  Richards, Anthony ^a,b   Herbst, Unine ^a,b   Manalang, Jane ^a,b   Pather, Selvan ^a,b,c   Saidi, Samir ^a,b,c   Tejada Berges, Trevor ^a,b,c   Tan, Kris ^b,c   Williams, Paul ^c   Carter, Jonathan ^a,b,c  

^a Chris O Brien Lifehouse   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CA125; HE4; ovarian cancer; risk of ovarian malignancy algorithm; risk of ovarian malignancy index

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; ALGORITHM; ARTICLE; AUSTRALIAN; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTADENOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIOSIS; FEMALE; GRANULOSA CELL TUMOR; HUMAN; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVARY TERATOMA; OVARY TUMOR; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ADVERSE EFFECTS; AGED; AREA UNDER THE CURVE; AUSTRALIA; BLOOD; COHORT ANALYSIS; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; PELVIC NEOPLASMS; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL ANALYSIS; THERAPY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; AUSTRALIA; BIOMARKERS, TUMOR; CA-125 ANTIGEN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; PELVIC NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS; RISK ASSESSMENT; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84942847922     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12363     Document Type: Article

References (22)

1. Penson RT, Wenzel LB, Vergote I, Cella D,. Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Supp 1): S247-S257.
2. Jacobs IJ, Menon U,. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-366.
3. Molina R, Ojeda B, Filella X, et al., A prospective study of tumor markers CA125 and CA19.9 in patients with epithelial ovarian carcinomas. Tumor Biol 1992; 13: 278-286.
4. Rosen DG, Wang L, Atkinson JN, et al., Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-277.
5. Jacobs I, Oram D, Fairbanks J, et al., A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97: 922-929.
6. van den Akker P, Aalders AL,. Evaluation of the risk of malignancy index in daily clinical management of adnexal masses. Gynecol Oncol 2010; 116: 384-388.
7. Kirchoff C, Habben I, Ivell R, Krull N,. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991; 45: 350-357.
8. Schummer M, Ng WV, Bumgarner RE, et al., Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999; 238: 375-385.
9. Karlsen MA, Sandhu N, Høgdall C, et al., Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012; 127: 379-383.
10. Sandri MT, Bottari F, Franchi D, et al., Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol 2013; 128: 233-238.
11. van Gorp T, Cadron I, Despierre E, et al., HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011; 104: 863-870.
12. Montagnana M, Danese E, Ruzzenente O, et al., The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49: 521-525.
13. Huhtinen K, Suvitie P, Hiissa J, et al., Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315-1319.
14. Moore RG, Brown AK, Miller MC, et al., The use of multiple tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402-408.
15. Escudero JM, Auge JM, Filella X, et al., Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011; 57: 1534-1544.
16. Kadija S, Stefanovic A, Jeremic K, et al., The utility of human epididymal protein 4, cancer antigen 125, and risl for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22: 238-244.
17. Wu L, Dai ZY, Qian YH, et al., Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer 2012; 22: 1106-1112.
18. Moore RG, Jabre-Raughley M, Brown AK, et al., Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: e1-e6.
19. Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, et al., Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol 2013; 129: 467-471.
20. Moore RG, McMeekin DS, Brown AK, et al., A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40-46.
21. Bast RC Jr, Badgwell D, Lu Z, et al., New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005; 15 (Suppl 3): 274-281.
22. Duffy MJ, Bonfrer JM, Kulpa J, et al., CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679-691.